An interventional study of Integrated skills and safety planning app in Suicidal Ideation and Suicidal Behavior, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Washington · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Suicidal Ideation by University of Washington — 3 open to participants now, 4 under way, none of them phase 3. Suicidal Ideation · University of Washington.
Among the 11 studies in Suicidal Ideation by University of Washington, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 9 with no phase, and was the 9th registered.
570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.
Browse Suicidal Ideation studies →3 of the 11 studies in Suicidal Ideation by University of Washington are open now, in 2 countries. Recruiting first, the newest first:
University of Washington · Sites in Mozambique
University of Washington · Sites in United States
Ages 13–21
By country, each count listing its studies:
Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 13 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 470 interventional studies indexed under Suicidal Ideation.
Median enrollment 60 across the 11 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
1 of the studies in Suicidal Ideation by University of Washington that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06701006University of WashingtonIntegrated Suicide Supports and Safety Planning for Youth | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Suicidal Ideation by University of Washington, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate an app to help keep teens and young adults with suicidal thoughts safe. The app includes a safety plan created by adolescents and healthcare providers, and videos to encourage supportive communication and skills for teens and young adults to stay safe. The main question it aims to answer is whether the use of an app can increase youth suicide-related coping for youth with suicidal ideation, parent/caregiver suicide prevention self-efficacy, and healthcare provider self-efficacy in suicide management. Researchers will compare usual care to usual care with the app. Participants, including adolescents, caregivers, and healthcare providers, will use the ISSP app (if assigned to that group) and view video content and complete three online surveys.
The current study aims to evaluate the Jaspr app relative to usual care among youth (ages 13-21 years) who indicate suicidal ideation in pediatric medical settings. The Jaspr app includes supported safety planning between the young person and the healthcare provider, as well as skills and support videos for youth and caregivers intended to increase coping and decrease distress with an opportunity to access these resources through an at home app. Adolescents, parents, and clinicians will participate in the project to assess the effectiveness of Jaspr augmenting usual care, compared to usual care alone. The study will use a pre-post design in which each setting begins with a control period and then transitions to the addition of Jaspr following healthcare provider training on use of the app. Participants and their parents/caregivers will receive study assessments at baseline, 1-month, and 2-month follow up timepoints, and healthcare providers complete a survey at baseline, and the end of each period (control and intervention). Study assessments with youth will ask about coping, suicidal ideation and severity, anxiety and depression, service utilization, functional impairment, access to lethal means, and acceptability of the app. Study assessments for parents/caregivers will ask about their self-efficacy in managing their youth's suicidality, acceptability of the videos/app, and service utilization for the youth. Healthcare providers will complete surveys assessing their self-efficacy in managing youth suicidality and feasibility of use of the app. Youth, their legal guardian, and healthcare providers each assent/consent to participate in the research procedures.
Youth Inclusion Criteria:
Youth Exclusion Criteria:
Use of Jaspr app for clinical care + at home
Other: Integrated skills and safety planning app
This is a digital app that includes supported safety planning resources in medical settings as well as coping skills and lived experience videos for adolescents, young adults and parents/caregivers that can be accessed while in the medical setting or at home.
Also known as: Jaspr
Youth Suicide-Related Coping
Total Score on the 17-item Youth Suicide-Related Coping Scale
Time frame: Baseline, 1 month, 2 month
Parent suicide prevention self-efficacy
Total score on the Parent suicide prevention self-efficacy scale
Time frame: Baseline, 1 month, 2 month
Healthcare provider self-efficacy in suicide management
Total score on the Provider suicide Intervention Questionnaire
Time frame: Baseline, end of control period, and end of intervention period
Safety Plan Quality
Safety Planning Scoring Algorithm (SPISA) based on youth medical chart review
Time frame: Up to 1 month
Youth Suicide Severity
Total score on the online self-report version of the Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Baseline, 1 month, 2 month
Youth Anxiety Symptoms
Total Score on Youth Self-Reported Generalized Anxiety Disorder -7 item scale
Time frame: Baseline, 1 month, 2 month
Intervention Acceptability
Youth and Parent Report on the Acceptability of Intervention Measure (AIM)
Time frame: Baseline, 1 month, 2 month
Functional Impairment
Total score on the youth reported EQ-5D-Y quality of life measure
Time frame: Baseline, 1 month, 2 month
Youth Suicidal ideation
Total Score on the Harkavy Asnis Suicide Scale ideation subscale (HASS-I),
Time frame: Baseline, 1 month, 2 month
Youth Depressive Symptoms
Total score on the Patient Health Questionnaire 9
Time frame: Baseline, 1 month, 2 month
Access to Lethal Means
BRFSS Module 17 - Youth report of access to a firearm
Time frame: 1 month
Intervention Feasibility
Healthcare Provider Report on the Feasibility of Intervention Measure (FIM)
Time frame: Baseline, 1 month, 2 month
Mental Health Services Use
Dichotomous rating of any mental health service use following baseline using chart review or indication based on parent or youth report on the Services Assessment for Children and Adolescents (SACA)
Time frame: Baseline, 2 months
Plan to share: Yes — We plan to share required elements with the NIMH NDA.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 282 non-industry interventional studies with no phase under Suicidal Ideation, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 15 months is below that.
Counting every sponsor, half of 291 studies reached it within 30 months; a quarter within 13 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Nov 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.